Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial

Giovanni Addolorato, Fabio Caputo, Katrin Skala, Henriette Walter, Otto Lesch

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.
Original languageEnglish
Pages (from-to)743-752
Number of pages10
JournalCNS Drugs
Volume28
DOIs
Publication statusPublished - 2014

Keywords

  • alcohol withdrawal syndrome
  • sodium oxybate

Fingerprint

Dive into the research topics of 'Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial'. Together they form a unique fingerprint.

Cite this